PMID- 25092985
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140805
LR  - 20211021
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 10
DP  - 2014
TI  - Lower serum brain-derived neurotrophic factor levels are associated with failure 
      to achieve remission in patients with major depression after escitalopram 
      treatment.
PG  - 1393-8
LID - 10.2147/NDT.S64913 [doi]
AB  - BACKGROUND: Remission, the primary goal of treatment for major depressive 
      disorder (MDD), is the absence of significant signs or symptoms and the return to 
      a state of normal functioning. A recent study found that the level of 
      brain-derived neurotrophic factor (BDNF) increased after antidepressant treatment 
      in remitted patients. This study evaluated serum BDNF levels in MDD patients with 
      chronic maintenance treatment, and compared these between remission and 
      nonremission groups. MATERIALS AND METHODS: Serum BDNF levels were measured in 34 
      MDD patients and 35 healthy controls. The severity of depression was measured 
      using the Hamilton Depression Rating Scale (Ham-D). The MDD patients were divided 
      into remission and nonremission groups according to a cutoff total Ham-D score of 
      either </=7 or </=6. RESULTS: Serum BDNF levels differed significantly between the 
      remission, nonremission, and healthy control groups (P<0.05). The Bonferroni post 
      hoc test confirmed that serum BDNF levels were significantly lower in the 
      nonremission group than in the healthy-control group (P<0.05), but did not differ 
      significantly between the remission and healthy-control groups. LIMITATIONS: This 
      study included a small sample, and measured serum BDNF levels in the MDD patients 
      at only one point during the maintenance treatment. CONCLUSION: This study found 
      that serum BDNF levels during maintenance treatment were lower in MDD patients 
      with failure to achieve remission than in controls, while the remitted subjects 
      had normalized serum BDNF levels. A lower level of serum BDNF during maintenance 
      treatment is associated with failure to achieve remission in patients with major 
      depression. Moreover, serum BDNF levels after chronic antidepressant treatment 
      can be used as a biological marker for detecting nonremission.
FAU - Lee, Bun-Hee
AU  - Lee BH
AD  - Department of Psychiatry, Gangnam Eulji Hospital, Eulji University, Seoul, South 
      Korea.
FAU - Park, Young-Min
AU  - Park YM
AD  - Department of Psychiatry, Ilsan Paik Hospital, Inje University College of 
      Medicine, Goyang, South Korea.
FAU - Um, Tae Hyun
AU  - Um TH
AD  - Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College 
      of Medicine, Goyang, South Korea.
FAU - Kim, Sollip
AU  - Kim S
AD  - Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College 
      of Medicine, Goyang, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20140723
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC4114913
OTO - NOTNLM
OT  - brain-derived neurotrophic factor
OT  - major depression
OT  - remission
EDAT- 2014/08/06 06:00
MHDA- 2014/08/06 06:01
PMCR- 2014/07/23
CRDT- 2014/08/06 06:00
PHST- 2014/08/06 06:00 [entrez]
PHST- 2014/08/06 06:00 [pubmed]
PHST- 2014/08/06 06:01 [medline]
PHST- 2014/07/23 00:00 [pmc-release]
AID - ndt-10-1393 [pii]
AID - 10.2147/NDT.S64913 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2014 Jul 23;10:1393-8. doi: 10.2147/NDT.S64913. 
      eCollection 2014.